<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-93165" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antitubercular Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muralidhara Reddy</surname>
            <given-names>Kona</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kona Muralidhara Reddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-93165.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Antitubercular medications: rifampin, isoniazid, pyrazinamide, and ethambutol are FDA approved to treat Mycobacterium tuberculosis infections. Antitubercular medications are a group of drugs used to treat tuberculosis. Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (M-TB), an acid-fast aerobic bacteria that can grow on gram stain as either gram-positive or gram-negative. This review will outline the indications, contraindications, and other aspects of these drugs.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of antitubercular therapy.</p></list-item><list-item><p>Describe the potential adverse effects of antitubercular therapy.</p></list-item><list-item><p>Review the risk factors for developing drug resistance to antitubercular therapy.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance antitubercular therapy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93165&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93165">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-93165.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Tuberculosis is a disease that results from infection with the bacteria&#x000a0;<italic toggle="yes">Mycobacterium tuberculosis</italic>. It most commonly affects the lungs but can also affect other areas of the body. The infection can be active or latent, with approximately 10% of latent infections progressing to active status. The disease is spread by droplets from speaking, coughing, and sneezing. In the past, the disease was colloquially known by the name consumption. Diagnosis is via chest X-ray, microbacterial cultures, and tuberculin skin test.<xref ref-type="bibr" rid="article-93165.r1">[1]</xref></p>
        <p>Anti-tubercular medications: rifampin, isoniazid, pyrazinamide, and ethambutol are FDA-approved&#x000a0;for the treatment of <italic toggle="yes">Mycobacterium tuberculosis </italic>infections.<xref ref-type="bibr" rid="article-93165.r2">[2]</xref>&#x000a0;The combination and duration on which medications to use for&#x000a0;therapy rely&#x000a0;on whether the patient has active or latent disease.<xref ref-type="bibr" rid="article-93165.r3">[3]</xref>&#x000a0;A feared complication of tuberculosis therapy is multi-drug-resistant tuberculosis(MDR-TB).&#x000a0;MDR-TB is distinguished from its resistance to first-line medications isoniazid and rifampin.<xref ref-type="bibr" rid="article-93165.r4">[4]</xref>&#x000a0;Therapy for MDR-TB is steadily advancing, and suggestions are continually changing.<xref ref-type="bibr" rid="article-93165.r5">[5]</xref>&#x000a0;Second-line drugs&#x000a0;that&#x000a0;are in common use for MDR-TB are kanamycin, capreomycin, and amikacin&#x000a0;via injections.<xref ref-type="bibr" rid="article-93165.r5">[5]</xref>&#x000a0;Fluoroquinolones such as levofloxacin, moxifloxacin, and gatifloxacin are also among the common second-line agents used when drug resistance develops to the first-line agents.<xref ref-type="bibr" rid="article-93165.r6">[6]</xref><xref ref-type="bibr" rid="article-93165.r7">[7]</xref>&#x000a0;Drugs that have recently&#x000a0;received FDA approval for multi-drug resistance TB are pretomanid, used in sequence with bedaquiline and linezolid.<xref ref-type="bibr" rid="article-93165.r5">[5]</xref><xref ref-type="bibr" rid="article-93165.r8">[8]</xref><xref ref-type="bibr" rid="article-93165.r9">[9]</xref><xref ref-type="bibr" rid="article-93165.r10">[10]</xref>&#x000a0;A more dangerous and uncommon type of MDR-TB is extensively multi-drug resistant tuberculosis(XDR-TB). This infection characteristically shows the resistance to first-line medications rifampin and isoniazid, one second-line aminoglycoside, and either of the fluoroquinolones.<xref ref-type="bibr" rid="article-93165.r11">[11]</xref><xref ref-type="bibr" rid="article-93165.r12">[12]</xref>&#x000a0;</p>
        <p>
<bold>First Line</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rifampin</p>
          </list-item>
          <list-item>
            <p>Isoniazid</p>
          </list-item>
          <list-item>
            <p>Pyrazinamide</p>
          </list-item>
          <list-item>
            <p>Ethambutol</p>
          </list-item>
        </list>
        <p>
<bold>Second Line</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Kanamycin (discontinued use in the USA)</p>
          </list-item>
          <list-item>
            <p>Streptomycin</p>
          </list-item>
          <list-item>
            <p>Capreomycin</p>
          </list-item>
          <list-item>
            <p>Amikacin<bold/></p>
          </list-item>
          <list-item>
            <p>Levofloxacin</p>
          </list-item>
          <list-item>
            <p>Moxifloxacin</p>
          </list-item>
          <list-item>
            <p>Gatifloxacin</p>
          </list-item>
        </list>
        <p>
<bold>MDR-TB</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bedaquiline</p>
          </list-item>
          <list-item>
            <p>Delamanid</p>
          </list-item>
          <list-item>
            <p>Linezolid</p>
          </list-item>
          <list-item>
            <p>Pretomanid</p>
          </list-item>
        </list>
        <p>The information presented in this overview article is high level; for more details on each specific agent, the reader is instructed to seek the Statpearls articles on the individual agents.</p>
      </sec>
      <sec id="article-93165.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Rifampin</bold>
</p>
        <p>Rifampin exerts its effects by reversibly inhibiting&#x000a0;DNA-dependent RNA polymerase, which further inhibits bacterial protein synthesis and transcription.<xref ref-type="bibr" rid="article-93165.r13">[13]</xref><xref ref-type="bibr" rid="article-93165.r14">[14]</xref><xref ref-type="bibr" rid="article-93165.r15">[15]</xref></p>
        <p>
<bold>Isoniazid</bold>
</p>
        <p>Isoniazid is a pro-drug that is converted to its active form metabolite by catalase-peroxidase and exerts its action by further inhibiting the biosynthesis of mycolic acid.<xref ref-type="bibr" rid="article-93165.r4">[4]</xref><xref ref-type="bibr" rid="article-93165.r16">[16]</xref></p>
        <p>
<bold>Pyrazinamide</bold>
</p>
        <p>Pyrazinamide's mechanism of action remains unknown and not fully understood.<xref ref-type="bibr" rid="article-93165.r17">[17]</xref>&#x000a0;Pyrazinamide is converted to its active form pyrazinoic acid and exerts its effect by inhibiting trans-translation and possibly coenzyme A synthesis needed for the bacteria to survive.<xref ref-type="bibr" rid="article-93165.r18">[18]</xref></p>
        <p>
<bold>Ethambutol</bold>
</p>
        <p>Ethambutol inhibits the enzyme arabinosyltransferases and&#x000a0;prevents&#x000a0;the biosynthesis of the mycobacterial cell wall.<xref ref-type="bibr" rid="article-93165.r19">[19]</xref><bold/></p>
        <p>
<bold><bold>Aminoglycosides (Strep</bold>tomycin,&#x000a0;Kanamycin, Amikacin)</bold>
</p>
        <p>Aminoglycosides&#x000a0;exert their action by binding to the 30S subunit of ribosomes and inhibiting the protein synthesis of the mycobacteria.<xref ref-type="bibr" rid="article-93165.r20">[20]</xref><xref ref-type="bibr" rid="article-93165.r21">[21]</xref></p>
        <p>
<bold><bold>Fluoroquinolones&#x000a0;(Levofloxacin</bold>, Moxifloxacin, Gatifloxacin)</bold>
</p>
        <p>Fluoroquinolones exert their effects by inhibiting DNA gyrase and topoisomerase IV, further inhibiting DNA synthesis within the bacteria.<xref ref-type="bibr" rid="article-93165.r22">[22]</xref></p>
      </sec>
      <sec id="article-93165.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Active Tuberculosis</bold>
</p>
        <p>During active disease, there are two phases for treatment: the initiation phase and the continuation phase.<xref ref-type="bibr" rid="article-93165.r23">[23]</xref><xref ref-type="bibr" rid="article-93165.r5">[5]</xref>&#x000a0;The&#x000a0;initiation phase consists of two months of rifampin, isoniazid, pyrazinamide, and ethambutol therapy.<xref ref-type="bibr" rid="article-93165.r5">[5]</xref>&#x000a0;This regimen&#x000a0;is administered orally daily for eight weeks for a total of 56 doses.&#x000a0; Once completed, isoniazid and rifampin are continued for an additional four-month for the continuation phase.<xref ref-type="bibr" rid="article-93165.r2">[2]</xref><xref ref-type="bibr" rid="article-93165.r5">[5]</xref>&#x000a0;This regimen is administered orally daily for 18&#x000a0;weeks for a total of&#x000a0;126 doses. For patients that cannot tolerate ethambutol, streptomycin can be substituted.<xref ref-type="bibr" rid="article-93165.r2">[2]</xref></p>
        <p>
<bold>Rifampin</bold>
<xref ref-type="bibr" rid="article-93165.r24">[24]</xref>
</p>
        <p>10 mg/kg /day</p>
        <p>The maximum dose: 600mg</p>
        <p>
<bold>Isoniazid</bold>
<xref ref-type="bibr" rid="article-93165.r24">[24]</xref>
</p>
        <p>5 mg/kg/day</p>
        <p>The maximum dose: 300mg</p>
        <p>
<bold>Pyrazinamide</bold>
<xref ref-type="bibr" rid="article-93165.r24">[24]</xref>
</p>
        <p>25 mg/kg/day</p>
        <p>Dosages are adjusted according to weight</p>
        <p>
<bold>Ethambutol</bold>
<xref ref-type="bibr" rid="article-93165.r24">[24]</xref>
</p>
        <p>15&#x000a0;to 20 mg/kg/day</p>
        <p>Dosages are adjusted according to weightSecond-line agents such as kanamycin, capreomycin, amikacin are administered as an injection, and fluoroquinolones such as moxifloxacin, gatifloxacin, and levofloxacin are administered orally. These agents are options when resistance to first-line medication develops.<xref ref-type="bibr" rid="article-93165.r25">[25]</xref></p>
        <p>
<bold>Latent Tuberculosis</bold>
</p>
        <p>The most typical and used&#x000a0;treatment for latent&#x000a0;tuberculosis is isoniazid therapy for a duration of nine months.<xref ref-type="bibr" rid="article-93165.r3">[3]</xref>&#x000a0;This&#x000a0;regimen is administered orally daily for nine months for a total of&#x000a0;270&#x000a0;doses. A three-month combination of isoniazid and rifampin or a fourth-month duration of rifampin monotherapy are also possibilities.<xref ref-type="bibr" rid="article-93165.r3">[3]</xref>&#x000a0;Isoniazid monotherapy can have an effect of greater than 90% on the latent disease if taken upon completion of the full nine-month duration.<xref ref-type="bibr" rid="article-93165.r26">[26]</xref>&#x000a0;Pyridoxine (vitamin B6) use is advised alongside isoniazid therapy, as isoniazid&#x000a0;use individually can cause peripheral neuropathy secondary to vitamin B6 deficiency.</p>
        <p>
<bold>Isoniazid</bold>
<xref ref-type="bibr" rid="article-93165.r24">[24]</xref>
<bold/>
</p>
        <p>5 mg/kg/day</p>
        <p>The maximum dose: 300mg</p>
        <p>
<bold>Vitamin B6</bold>
<xref ref-type="bibr" rid="article-93165.r23">[23]</xref>
</p>
        <p>10 to 25 mg/day</p>
        <p>Anti-tubercular medications should be taken in the daytime one hour before consuming any meals.<xref ref-type="bibr" rid="article-93165.r2">[2]</xref></p>
      </sec>
      <sec id="article-93165.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Rifampin</bold>
<xref ref-type="bibr" rid="article-93165.r5">[5]</xref>
<xref ref-type="bibr" rid="article-93165.r27">[27]</xref>
<xref ref-type="bibr" rid="article-93165.r28">[28]</xref>
<xref ref-type="bibr" rid="article-93165.r24">[24]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Neutropenia</p>
          </list-item>
          <list-item>
            <p>Orange/Red discoloration of bodily fluids</p>
          </list-item>
          <list-item>
            <p>CYP450 Inducer</p>
          </list-item>
        </list>
        <p>
<bold>Isoniazid</bold>
<xref ref-type="bibr" rid="article-93165.r26">[26]</xref>
<xref ref-type="bibr" rid="article-93165.r29">[29]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Vitamin B6 deficiency</p>
          </list-item>
          <list-item>
            <p>Peripheral Neuropathy</p>
          </list-item>
        </list>
        <p>
<bold>Pyrazinamide</bold>
<xref ref-type="bibr" rid="article-93165.r27">[27]</xref>
<xref ref-type="bibr" rid="article-93165.r30">[30]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Hyperuricemia</p>
          </list-item>
          <list-item>
            <p>Arthralgia</p>
          </list-item>
        </list>
        <p>
<bold>Ethambutol</bold>
<xref ref-type="bibr" rid="article-93165.r31">[31]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Optic neuropathy</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
        </list>
        <p><bold><bold><bold>Aminoglycosides (Strep</bold>tomycin,&#x000a0;Kanamycin, Amikacin)</bold></bold>
<xref ref-type="bibr" rid="article-93165.r23">[23]</xref><xref ref-type="bibr" rid="article-93165.r32">[32]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Ototoxicity</p>
          </list-item>
          <list-item>
            <p>Nephrotoxicity</p>
          </list-item>
        </list>
        <p>
<bold><bold>Fluoroquinolones&#x000a0;(Levofloxacin</bold>, Moxifloxacin, Gatifloxacin)</bold>
<xref ref-type="bibr" rid="article-93165.r33">[33]</xref>
<bold/>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tendonitis</p>
          </list-item>
          <list-item>
            <p>Tendon rupture</p>
          </list-item>
          <list-item>
            <p>Arthropathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93165.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p><bold>Pregnancy</bold>: During pregnancy, all anti-tubercular medications are useful for treatment except for aminoglycosides.<xref ref-type="bibr" rid="article-93165.r23">[23]</xref>&#x000a0;Aminoglycosides such as streptomycin, amikacin, and kanamycin may exhibit ototoxic effects on the developing fetus and are contraindicated during pregnancy.<xref ref-type="bibr" rid="article-93165.r23">[23]</xref></p>
        <p>In the USA, pyrazinamide use is avoided during pregnancy because it is a possible teratogen.</p>
      </sec>
      <sec id="article-93165.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Liver function tests should be monitored routinely as rifampin, isoniazid, pyrazinamide, and ethambutol all may exert hepatotoxic effects.<xref ref-type="bibr" rid="article-93165.r27">[27]</xref>&#x000a0;A CBC is also required to regularly monitor&#x000a0;patients taking rifampin, as it can&#x000a0;lead to thrombocytopenia and neutropenia.<xref ref-type="bibr" rid="article-93165.r27">[27]</xref>&#x000a0;Rifampin&#x000a0;also exerts its effects by&#x000a0;inducing cytochrome P450(CYP450), which may cause unwanted drug interactions of medications that are metabolized by the CYP450 system and decrease their clinical efficacy.<xref ref-type="bibr" rid="article-93165.r28">[28]</xref>&#x000a0;Isoniazid can cause pyridoxine deficiency that may lead to peripheral neuropathy in patients.<xref ref-type="bibr" rid="article-93165.r29">[29]</xref>&#x000a0;The patient can supplement vitamin B6 to prevent this from happening.<xref ref-type="bibr" rid="article-93165.r29">[29]</xref>&#x000a0;Pyrazinamide can increase uric acid concentrations and precipitate acute gout flare-ups in predisposed individuals.<xref ref-type="bibr" rid="article-93165.r34">[34]</xref>&#x000a0;The recommendation is to monitor uric acid concentrations routinely for patients managed with pyrazinamide.<xref ref-type="bibr" rid="article-93165.r35">[35]</xref></p>
      </sec>
      <sec id="article-93165.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>All first-line anti-tubercular medications, rifampin, isoniazid, pyrazinamide, and ethambutol, can exert hepatotoxic effects.<xref ref-type="bibr" rid="article-93165.r27">[27]</xref><xref ref-type="bibr" rid="article-93165.r36">[36]</xref>&#x000a0;A continual rise in liver functions test should prompt discontinuation of treatment.<xref ref-type="bibr" rid="article-93165.r27">[27]</xref>&#x000a0;Aminoglycoside-induced nephrotoxicity is reversible when stopping the medication.<xref ref-type="bibr" rid="article-93165.r37">[37]</xref>&#x000a0;Renal toxicity&#x000a0;depends&#x000a0;on the&#x000a0;patient if any&#x000a0;underlying renal disease is present and on the dose of the medication being administered. Renal insufficiency is avoidable in most patients.<xref ref-type="bibr" rid="article-93165.r37">[37]</xref></p>
      </sec>
      <sec id="article-93165.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Rifampin, isoniazid, pyrazinamide, and ethambutol are first-line antitubercular medications, which are FDA-approved and indicated for the treatment of <italic toggle="yes">Mycobacterium tuberculosis</italic> infections. The care for patients suffering from tuberculosis prompts critical care from an interprofessional team of healthcare professionals as the preventable infectious disease can lead to medication resistance and mortality. These healthcare professionals include a primary care clinician, an infectious disease specialist, a nurse, and a pharmacist. The primary care physicians and specialists should educate the patients about the consequences of non-adherence to pharmacotherapy for the full duration and how resistance to treatment can further develop into MDR-TB and cause mortality.</p>
        <p>Primary care clinicians should routinely monitor labs, as all four agents are hepatotoxic drugs. Counseling and&#x000a0;careful monitoring&#x000a0;should be&#x000a0;conducted during pregnancy, as some second-line medications are teratogenic. Clinicians should be up to date with the newly FDA-approved MDR-TB and their effects in the event drug resistance develops. Interprofessional communication between all team members is key to building patient rapport and developing a therapeutic alliance, so the patients adhere to therapy adequately&#x000a0;to eradicate the bacteria&#x000a0;and prevent&#x000a0;further spread. This interprofessional approach with open communication channels between team members will drive better patient outcomes with fewer adverse events. [Level 5]</p>
      </sec>
      <sec id="article-93165.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93165&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93165">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/93165/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=93165">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-93165.s11">
        <title>References</title>
        <ref id="article-93165.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Alzayer</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Al Nasser</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <chapter-title>Primary Lung Tuberculosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">33620814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben Amar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dhahri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aouina</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Azzabi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baccar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>El Gharbi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bouacha</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Treatment of tuberculosis].</article-title>
            <source>Rev Pneumol Clin</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>71</volume>
            <issue>2-3</issue>
            <fpage>122</fpage>
            <page-range>122-9</page-range>
            <pub-id pub-id-type="pmid">25434510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parekh</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Schluger</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Treatment of latent tuberculosis infection.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>351</fpage>
            <page-range>351-6</page-range>
            <pub-id pub-id-type="pmid">24056289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unissa</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Subbian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Selvakumar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.</article-title>
            <source>Infect Genet Evol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>45</volume>
            <fpage>474</fpage>
            <page-range>474-492</page-range>
            <pub-id pub-id-type="pmid">27612406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bloom</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Atun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dye</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nardell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vassall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Volchenkov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Tuberculosis</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bertozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <source>Major Infectious Diseases</source>
            <edition>3rd</edition>
            <publisher-name>The International Bank for Reconstruction and Development / The World Bank</publisher-name>
            <publisher-loc>Washington (DC)</publisher-loc>
            <year>2017</year>
            <month>11</month>
            <day>03</day>
            <pub-id pub-id-type="pmid">30212088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berning</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>The role of fluoroquinolones in tuberculosis today.</article-title>
            <source>Drugs</source>
            <year>2001</year>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-18</page-range>
            <pub-id pub-id-type="pmid">11217874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moadebi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harder</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Elwood</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolones for the treatment of pulmonary tuberculosis.</article-title>
            <source>Drugs</source>
            <year>2007</year>
            <volume>67</volume>
            <issue>14</issue>
            <fpage>2077</fpage>
            <page-range>2077-99</page-range>
            <pub-id pub-id-type="pmid">17883288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mase</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chorba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belanger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dworkin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Seaworth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States.</article-title>
            <source>Clin Infect Dis</source>
            <year>2020</year>
            <month>Aug</month>
            <day>14</day>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>1010</fpage>
            <page-range>1010-1016</page-range>
            <pub-id pub-id-type="pmid">31556947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Droc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stefan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>FDA approved antibacterial drugs: 2018-2019.</article-title>
            <source>Discoveries (Craiova)</source>
            <year>2019</year>
            <month>Dec</month>
            <day>31</day>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>e102</fpage>
            <pub-id pub-id-type="pmid">32309620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riccardi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Del Puente</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Magn&#x000e8;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Taramasso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Biagio</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.</article-title>
            <source>Recent Pat Antiinfect Drug Discov</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-11</page-range>
            <pub-id pub-id-type="pmid">28625141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Yew</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.</article-title>
            <source>Respirology</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-21</page-range>
            <pub-id pub-id-type="pmid">22943408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dheda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Guglielmetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Furin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Chesov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Esmail</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>131</fpage>
            <page-range>131-140</page-range>
            <pub-id pub-id-type="pmid">27756712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lancini</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of rifampin on Mycobacterium smegmatis.</article-title>
            <source>J Bacteriol</source>
            <year>1971</year>
            <month>Nov</month>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>737</fpage>
            <page-range>737-41</page-range>
            <pub-id pub-id-type="pmid">4942761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wehrli</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Staehelin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Actions of the rifamycins.</article-title>
            <source>Bacteriol Rev</source>
            <year>1971</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <page-range>290-309</page-range>
            <pub-id pub-id-type="pmid">5001420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yura</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effects of rifampicin on synthesis and functional activity of DNA-dependent RNA polymerase in Escherichia coli.</article-title>
            <source>Mol Gen Genet</source>
            <year>1976</year>
            <month>Jun</month>
            <day>15</day>
            <volume>145</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-37</page-range>
            <pub-id pub-id-type="pmid">781514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De La Iglesia</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Morbidoni</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>[Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends].</article-title>
            <source>Rev Argent Microbiol</source>
            <year>2006</year>
            <season>Apr-Jun</season>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-109</page-range>
            <pub-id pub-id-type="pmid">17037259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dillon</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Feaga</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Keiler</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Baughn</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Jul</month>
            <day>21</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>6135</fpage>
            <pub-id pub-id-type="pmid">28733601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mitchison</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Pyrazinamide Action and Resistance.</article-title>
            <source>Microbiol Spectr</source>
            <year>2013</year>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">25530919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goude</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parish</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>4138</fpage>
            <page-range>4138-46</page-range>
            <pub-id pub-id-type="pmid">19596878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vianna</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>S Bezerra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>I N Oliveira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Albuquerque</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Fulco</surname>
                <given-names>UL</given-names>
              </name>
            </person-group>
            <article-title>Binding energies of the drugs capreomycin and streptomycin in complex with tuberculosis bacterial ribosome subunits.</article-title>
            <source>Phys Chem Chem Phys</source>
            <year>2019</year>
            <month>Sep</month>
            <day>21</day>
            <volume>21</volume>
            <issue>35</issue>
            <fpage>19192</fpage>
            <page-range>19192-19200</page-range>
            <pub-id pub-id-type="pmid">31436279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prokhorova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Djumagulov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Urzhumtsev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Yusupov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Yusupova</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycoside interactions and impacts on the eukaryotic ribosome.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2017</year>
            <month>Dec</month>
            <day>19</day>
            <volume>114</volume>
            <issue>51</issue>
            <fpage>E10899</fpage>
            <page-range>E10899-E10908</page-range>
            <pub-id pub-id-type="pmid">29208708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drlica</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolone-Gyrase-DNA Cleaved Complexes.</article-title>
            <source>Methods Mol Biol</source>
            <year>2018</year>
            <volume>1703</volume>
            <fpage>269</fpage>
            <page-range>269-281</page-range>
            <pub-id pub-id-type="pmid">29177748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <collab>API Consensus Expert Committee</collab>
            <article-title>API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.</article-title>
            <source>J Assoc Physicians India</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>54</volume>
            <fpage>219</fpage>
            <page-range>219-34</page-range>
            <pub-id pub-id-type="pmid">16800350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boeree</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Heinrich</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aarnoutse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Diacon</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rehal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kibiki</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Churchyard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sanne</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ntinginya</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Minja</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Charalambous</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hanekom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Semvua</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Mpagama</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Manyama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mtafya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reither</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wallis</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Venter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narunsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mekota</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colbers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Balen</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>PPJ</given-names>
              </name>
              <name>
                <surname>Hoelscher</surname>
                <given-names>M</given-names>
              </name>
              <collab>PanACEA consortium</collab>
            </person-group>
            <article-title>High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-49</page-range>
            <pub-id pub-id-type="pmid">28100438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fan</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>XW</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>FZ</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolone derivatives and their anti-tubercular activities.</article-title>
            <source>Eur J Med Chem</source>
            <year>2018</year>
            <month>Feb</month>
            <day>25</day>
            <volume>146</volume>
            <fpage>554</fpage>
            <page-range>554-563</page-range>
            <pub-id pub-id-type="pmid">29407980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lobue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treatment of latent tuberculosis infection: An update.</article-title>
            <source>Respirology</source>
            <year>2010</year>
            <month>May</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>603</fpage>
            <page-range>603-22</page-range>
            <pub-id pub-id-type="pmid">20409026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schonell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dorken</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grzybowski</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rifampin.</article-title>
            <source>Can Med Assoc J</source>
            <year>1972</year>
            <month>Apr</month>
            <day>08</day>
            <volume>106</volume>
            <issue>7</issue>
            <fpage>783</fpage>
            <page-range>783-6</page-range>
            <pub-id pub-id-type="pmid">4622757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baciewicz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chrisman</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Finch</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Update on rifampin, rifabutin, and rifapentine drug interactions.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">23136913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snider</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine supplementation during isoniazid therapy.</article-title>
            <source>Tubercle</source>
            <year>1980</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>191</fpage>
            <page-range>191-6</page-range>
            <pub-id pub-id-type="pmid">6269259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>AQ</given-names>
              </name>
              <name>
                <surname>Doan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pyrazinamide-induced hyperuricemia.</article-title>
            <source>P T</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>10</issue>
            <fpage>695</fpage>
            <page-range>695-715</page-range>
            <pub-id pub-id-type="pmid">25336865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamberlain</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Sadaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol optic neuropathy.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>545</fpage>
            <page-range>545-551</page-range>
            <pub-id pub-id-type="pmid">28759559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wargo</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycoside-induced nephrotoxicity.</article-title>
            <source>J Pharm Pract</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>573</fpage>
            <page-range>573-7</page-range>
            <pub-id pub-id-type="pmid">25199523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stephenson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Tendon Injury and Fluoroquinolone Use: A Systematic Review.</article-title>
            <source>Drug Saf</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>709</fpage>
            <page-range>709-21</page-range>
            <pub-id pub-id-type="pmid">23888427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kurasawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshimatsu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Hyperuricemia and arthralgia during pyrazinamide treatment].</article-title>
            <source>Nihon Kokyuki Gakkai Zasshi</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-8</page-range>
            <pub-id pub-id-type="pmid">10214039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x0015e;i&#x0015f;manlar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Budako&#x0011f;lu</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?</article-title>
            <source>J Trop Pediatr</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>351</fpage>
            <page-range>351-6</page-range>
            <pub-id pub-id-type="pmid">26136257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>2018</year>
            <month>Mar</month>
            <day>04</day>
            <volume>497</volume>
            <issue>2</issue>
            <fpage>485</fpage>
            <page-range>485-491</page-range>
            <pub-id pub-id-type="pmid">29454961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93165.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabrizii</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thalhammer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>H&#x000f6;rl</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>[Aminoglycoside-induced nephrotoxicity].</article-title>
            <source>Wien Klin Wochenschr</source>
            <year>1997</year>
            <month>Nov</month>
            <day>14</day>
            <volume>109</volume>
            <issue>21</issue>
            <fpage>830</fpage>
            <page-range>830-5</page-range>
            <pub-id pub-id-type="pmid">9454436</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
